Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...
GLP-1 therapies continue to reshape chronic disease treatment, triggering regulatory updates, new clinical findings and intensifying competition across the pharmaceutical market. On Jan. 13, the FDA ...
Combat muscle loss with this 7-move routine.
In a new trial, people who switched to the experimental daily GLP-1 pill orforglipron were able to keep off most of the weight they had lost taking Wegovy or Zepbound. People who switched from Wegovy ...
As GLP‑1 drugs transform consumer diets in real time, food companies are racing to build products that nourish, satisfy and ...
Telehealth company eMed has partnered with CVS Caremark to offer a GLP-1 benefit model that lets employers subsidize weight loss medications without covering the full cost, Axios reported Feb. 16. The ...
INDIANAPOLIS — It’s just days before Christmas as medical workers wheel 7-year-old Jessa Milender through the halls of the hospital. The normally bubbly child is limp, face-down on a medical gurney.
What will the future world of GLP-1 drugs look like? From Eli Lilly's Foundayo to triple-strength Wegovy, discover the ...
Evidence is mounting that the wildly popular weight-loss medicines known as GLP-1s may also hold potential for treating addiction, and the field may be on the verge of obtaining desperately needed ...
GLP-1 medications have reached a level of household penetration that food and beverage brands can no longer ignore, but the impact on grocery sales is unfolding more gradually than some might expect.
The growth potential in the GLP-1 market could help healthcare stocks soar in value. Competition, however, is likely to be fierce. Many drugs offer comparable weight loss. Healthcare companies have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results